摘要
目的系统评价非小细胞肺癌患者中XRCC1基因多态性与铂类药物化学治疗敏感性的相关性。方法计算机检索中国生物医学文献数据库(CBM)、中国学术期刊全文数据库(CNKI)和中文科技期刊全文数据库维普(VIP)、万方数据库、Pubmed和EMBASE等数据库,检索时间为1978年1月至2012年6月。在提取资料和评价质量后,用RevMan5.1.4软件进行Meta分析。结果共纳入17个研究,合计1 807例患者。Meta分析结果显示,XRCC1基因194位点TT基因型[TT vs.CC,OR=2.08,95%CI(1.40-3.09)]和CT基因型[CT vs CC,OR=2.12,95%CI(1.62-2.76)]的患者化学治疗有效率都明显高于CC基因型的患者,而且变异型(CT+TT基因型)的患者化学治疗有效率明显高于野生型(CC)基因型的患者[TT+CT vs CC,OR=2.14;95%CI(1.67-2.75)];XRCC1 399位点的AA基因型化学治疗敏感性低于GG基因型[AA vs GG,OR=0.52,95%CI(0.33-0.83)],而且XRCC1 399位点变异型(AA+AG基因型)化学治疗敏感性低于野生型(GG基因型)[AA+AG vs GG,OR=0.53,95%CI(0.34-0.81)]。然而,XRCC1 399位点的AG基因型与GG基因型之间没有显著性差异[AG vs GG,OR=0.69,95%CI(0.45-1.06)]。结论非小细胞肺癌患者中XRCC1基因多态性与铂类药物化学治疗敏感性相关。
Objective To evaluate the relationship between the polymorphisms in XRCC1 gene and the sensitivity of platinum- based chemotherapy for the patients with non-small cell lung cancer. Methods The Pubmed, EMBASE, CBM, CNKI, VIP and Wangfang database were retrieved from January 1978 to June 2012. After extracting the data and conducting the quality evaluation,the meta anal- ysis was performed by RevMan 5. 1.4 software. Results A total of 17 trials involving 1 807 patients were included. The meta analysis results showed that the effective rate of the chemotherapy in the patients with the TF genotype （T1~ vs. CC： 0R,2.08;95% CI, 1.40- 3.09）,the CT genotype （CT vs. CC：OR,2.12;95% CI,1.62-2.76） and the CT＋TF genotypes （TF＋CT vs. CC：OR,2.14;95% CI, 1.67-2.75） at XRCC1 Arg194Trp was significantly higher than that in the patients with the CC genotype. The chemotherapeutic sen- sitivity in the patients with AA genotype [AA vs. GG ： OR, 0. 52 ; 95% CI, 0. 33 - 0.83 ] and the AA ＋ AG genotype[ AA ＋ AG vs. GG： OR, 0.53;95% C/,0.34-0.81]at XRCC1 Arg399Gln was tower than that in the patiems with the GG genetype. There was no significant difference in the sensitivity between the AG genotype and the GG genotype at XRCC1 Arg399Gln[AG vs. GG： OR, 0. 69; 95%CI, 0.45- 1.06]. Conclusion The polymorphism in XRCC1 gene is associated with the sensitivity of platinum- based chemotherapy in the patients with non- small cell lung cancer.
出处
《中国药业》
CAS
2013年第20期26-31,共6页
China Pharmaceuticals
